Last reviewed · How we verify
NCT04594473: CORE
A Comprehensive Oncology Rehabilitation and Exercise (CORE) Program Among Breast Cancer Survivors
NA trial testing Comprehensive Oncology Rehabilitation and Exercise (CORE) Program in Breast Cancer in 72 participants. Completed in 10 November 2023.
10 November 2023
Quick facts
| Lead sponsor | University of Utah |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 72 |
| Start date | 24 March 2021 |
| Primary completion | 10 November 2023 |
| Estimated completion | 10 November 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Comprehensive Oncology Rehabilitation and Exercise (CORE) Program
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
University of Utah
Who can join
18 and older, any sex, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this study is to demonstrate the feasibility and acceptability of the algorithm utilized within a cancer rehab program, named Comprehensive Oncology Rehabilitation and Exercise (CORE) program, among newly diagnosed stage I-III breast cancer survivors, providers, and clinic staff. Additionally, this study aims to generate preliminary estimates on the extent to which CORE, compared with standard of care (SOC), elicits engagement in exercise and impacts changes in physical function and quality of life within this population.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Feasibility and acceptability of the Comprehensive Oncology Rehabilitation and Exercise (CORE) clinical workflow algorithm in patients with newly diagnosed stage I-III breast cancer who undergo surgery as first-line treatment.
Simon LH, Saviers-Steiger C, Dunston ER, Galyean P, et al · · 2025 · cited 2× · PMID 40289623 · DOI 10.1002/cncr.35798
Verify or expand the search:
- PubMed search for NCT04594473
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other University of Utah trials
Trials by the same sponsor.
- NCT07515755 — Supplemental Oxygen and Oxygen Desaturations in Colonoscopies · NA · not yet recruiting
- NCT07225426 — Personalizing Financial Incentives · NA · recruiting
- NCT06716411 — Confirming the Effects of Acupuncture Treatments to Relieve Symptoms of Gulf War Illness · NA · recruiting
- NCT07246538 — Positive Airway Pressure (PAP) System Evaluation in Volunteers · NA · not yet recruiting
- NCT04208984 — Diversion Device With Breath Control · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04594473 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Utah
- Last refreshed: 16 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04594473.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing